PT  - JOURNAL ARTICLE
AU  - Célia Sentis
AU  - Geneviève Billaud
AU  - Antonin Bal
AU  - Emilie Frobert
AU  - Maude Bouscambert
AU  - Gregory Destras
AU  - Laurence Josset
AU  - Bruno Lina
AU  - Florence Morfin
AU  - Alexandre Gaymard
AU  - the COVID-Diagnosis HCL Study Group
TI  - SARS-CoV-2 Omicron variant, lineage BA.1, is associated with lower viral load in nasopharyngeal samples compared to Delta variant
AID  - 10.1101/2022.02.02.22269653
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.02.22269653
4099  - http://medrxiv.org/content/early/2022/02/03/2022.02.02.22269653.short
4100  - http://medrxiv.org/content/early/2022/02/03/2022.02.02.22269653.full
AB  - High viral load in upper respiratory tract specimens observed for Delta cases may contributed to its increased infectivity compared to the Alpha variant. Herein, we showed that the RT-PCR Ct values in Health Care Workers sampled within five days after symptom onset were significantly higher for Omicron cases than Delta cases (+2.84 Ct, p=0.008). This result comfort the studies showing that the increased transmissibility of Omicron is related to other mechanisms than higher virus excretion.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Hospices Civils de Lyon gave ethical approval for this work (approval number 22_787). The investigations were carried out in accordance with the General Data Protection Regulation (Regulation (EU) 2016/679 and Directive 95/46/EC) and the French data protection law (Law 78.17 on 06/01/1978 and Decret 2019.536 on 29/05/2019). Samples were collected for regular clinical management, with no additional samples for the purpose of this study. Patients were informed and their non-objection approval was confirmed. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors